Evaluation of the Antitrypanosomal Activity of the Crude Extracts of Uvaria Ovata: In vitro and In silico Approach

Authors:

Abstract
Background: Human African trypanosomiasis is the third disease with most mortalities among the neglected tropical diseases. The absence of vaccines and the development of parasite resistance have necessitated the quest for new affordable and safe treatment options for the disease. This study aims to assess the potential ofUvaria ovataas an alternative new and safer antitrypanosomal therapeutics.Methods: Antitrypanosomal efficacies of extracts and fractions ofU. ovatawere determined by the Alamar Blue cell viability assay againstTrypanosoma brucei bruceiGUTat 3.1. Molecular docking was used to suggest the mechanism of action of the extracts and fractions by docking the curated compounds present in the plant against farnesyl diphosphate synthase (FPPS) and ornithine decarboxylase (ODC) enzymes.Results: Antitrypanosomal activities (IC50, μg/mL) obtained were within the range of 0.12–4.40, exceeding that of the standard suramin (4.96). A total of 17 known compounds fromU. ovatathat did not violate Lipinski’s rule of five with negligible toxicity produced molecular docking results against FPPS and ODC enzymes. Within the FPPS interaction landscape, mannosamine emerged as the most promising lead, with a binding energy of −6.4 kcal/mol and a predicted Ki value of 20.12 μM. With respect to ODC, 15 compounds exhibited binding affinities ranging from −4.6 to −6.3 kcal/mol, exceeding that of the known inhibitor allicin (−4.5 kcal/mol).Conclusion: This is the first report of the antitrypanosomal activity and mode of action suggestion ofU. ovata. The study sets the foundation for further exploration and validation of the therapeutic prospect ofU. ovatain the fight against trypanosomiasis.

This publication has 33 references indexed in Scilit: